{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:10:51Z","timestamp":1792066251320,"version":"4.4.0"},"reference-count":68,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010414","name":"Health Research Board","doi-asserted-by":"publisher","award":["APRO-2023-005"],"award-info":[{"award-number":["APRO-2023-005"]}],"id":[{"id":"10.13039\/100010414","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People taking antipsychotic medicines and those with severe mental illness experience elevated cardiovascular risk compared to the general population which is not adequately addressed by existing guidelines. Increases in lipid levels can occur soon after starting antipsychotics but often go untreated. Cumulative exposure to dyslipidemia from childhood, through young adulthood, facilitates atherogenesis. Regression of early lesions is possible; however, plaque progression can be irreversible, leading to sustained long-term cardiovascular risk. Although lipid-lowering therapies are effective at lowering cardiovascular risk, they are underutilized in this population. We have thus developed a clinical practice guideline for the pharmacological management of antipsychotic-related dyslipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>Using GRADE-ADOLOPMENT methodology, an international, multidisciplinary panel including experts-by-experience, developed a guideline for the pharmacological management of antipsychotic-related dyslipidemia. Literature was reviewed to answer key health questions. Patient important outcomes were identified. An evidence-to-decision framework informed the strength of recommendations and external reviews evaluated the rigor of the methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>Seven recommendations were developed on how and when to initiate lipid-lowering therapy based on specific criteria including established cardiovascular disease\/high-risk conditions, cardiovascular risk assessment, or lipid parameter thresholds. A guideline algorithm illustrates the recommendations alongside supporting prescribing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first clinical practice guideline for the management of antipsychotic-related dyslipidemia. The inclusion of recommendations for individuals aged 10\u00a0years and over represents a significant development. Implementation will be supported by shared decision-making resources including information videos and decision-aids.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbag086","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:19:50Z","timestamp":1777637990000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Practice Guideline on the Pharmacological Management of Antipsychotic-Related Dyslipidemia"],"prefix":"10.1093","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-1489","authenticated-orcid":false,"given":"Aoife","family":"Carolan","sequence":"first","affiliation":[{"name":"Pharmacy Department, St John of God University Hospital , Dublin A94 FH92 ,","place":["Ireland"]},{"name":"Research and Innovation Hub, St John of God University Hospital , Dublin A94 FH92 ,","place":["Ireland"]},{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 YN77 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hynes-Ryan","sequence":"additional","affiliation":[{"name":"Pharmacy Department, St John of God University Hospital , Dublin A94 FH92 ,","place":["Ireland"]},{"name":"Research and Innovation Hub, St John of God University Hospital , Dublin A94 FH92 ,","place":["Ireland"]},{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 YN77 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Bourke","sequence":"additional","affiliation":[{"name":"PROGRESS Research Group, UCD Centre for Psychosis Research, School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Columb","sequence":"additional","affiliation":[{"name":"Lucena Clinic Tallaght , Dublin D24 V260 ,","place":["Ireland"]},{"name":"School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Cullen","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"deFerranti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harvard Medical School , Boston, MA 02115 ,","place":["United States"]},{"name":"Department of Cardiology, Boston Children's Hospital , Boston, MA 02115 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie Mae","family":"Harrington","sequence":"additional","affiliation":[{"name":"PROGRESS Research Group, UCD Centre for Psychosis Research, School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]},{"name":"Studio III Clinical Services , Kerry V92PP8 ,","place":["Ireland"]},{"name":"WHO Youth Advisory Group, Quality of Child and Adolescent Mental Healthcare, WHO Country Office , 10675 Athens ,","place":["Greece"]},{"name":"SpunOut , Dublin D02 T883 ,","place":["Ireland"]},{"name":"Youthmed.info, St John of God University Hospital , Dublin A94 FH92 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Kelleher","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]},{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh , Edinburgh, EH16 4TJ ,","place":["United Kingdom"]},{"name":"Research Unit of Clinical Medicine, University of Oulu , 90220 Oulu ,","place":["Finland"]},{"name":"St John of God Hospitaller Services Group, Stillorgan , Dublin A94 X5K8 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2577-0242","authenticated-orcid":false,"given":"Cormac","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Therapeutics, Health Sciences Centre, St James's Hospital , Dublin D08 W9RT ,","place":["Ireland"]},{"name":"School of Medicine, Trinity College Dublin , Dublin D02 XH97 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Alberta , Stollery Children's Hospital, Edmonton, AB T6G 2B7 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lally","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]},{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London , London, SE5 8AF ,","place":["United Kingdom"]},{"name":"Department of Psychiatry, St Vincent\u2019s Hospital Fairview , Dublin D03 XK40 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lyne","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, RCSI University of Medicine and Health Sciences , Dublin D02 YN77 ,","place":["Ireland"]},{"name":"Newcastle Hospital , Co. Wicklow A63 CD30 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Norton","sequence":"additional","affiliation":[{"name":"PROGRESS Research Group, UCD Centre for Psychosis Research, School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"RISE, Early Intervention in Psychosis Team, South Lee Mental Health Services , Cork T12 YEO2 ,","place":["Ireland"]},{"name":"Department of Psychiatry and Neurobehavioral Science, University College Cork , Cork T12 K8AF ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"School of Medicine, Trinity College Dublin , Dublin D02 XH97 ,","place":["Ireland"]},{"name":"Department of Pharmacology and Therapeutics, St James's Hospital , Dublin D08 W9RT ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]},{"name":"Department of Endocrinology, St Vincent\u2019s University Hospital , Dublin D04 T6F4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Perry","sequence":"additional","affiliation":[{"name":"Institute for Mental Health, University of Birmingham , Birmingham B15 2TT ,","place":["United Kingdom"]},{"name":"Birmingham Early Intervention Services, Birmingham and Solihull Mental Health NHS Foundation Trust , Birmingham B13 8QY ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Prendeville","sequence":"additional","affiliation":[{"name":"Children\u2019s Health Ireland, Our Lady's Children's Hospital, Crumlin , Dublin D12 N512 ,","place":["Ireland"]},{"name":"College of Medicine, Nursing & Health Sciences, University of Galway , Galway H91 F677 ,","place":["Ireland"]},{"name":"School of Medicine , Dentistry and Biomedical Sciences, , Belfast BT7 1NN ,","place":["United Kingdom"]},{"name":"Queens University , Dentistry and Biomedical Sciences, , Belfast BT7 1NN ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristin","family":"Ryan","sequence":"additional","affiliation":[{"name":"The School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, University of Dublin , Dublin D02 XH97 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Sadowska","sequence":"additional","affiliation":[{"name":"PROGRESS Research Group, UCD Centre for Psychosis Research, School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shiers","sequence":"additional","affiliation":[{"name":"Psychosis Research Unit, Greater Manchester Mental Health NHS Trust Rico House , Manchester M25 9WS ,","place":["United Kingdom"]},{"name":"School of Health Sciences , Division of Psychology and Mental Health, , Manchester M13 9PL ,","place":["United Kingdom"]},{"name":"University of Manchester , Division of Psychology and Mental Health, , Manchester M13 9PL ,","place":["United Kingdom"]},{"name":"School of Medicine, Keele University , Newcastle ST5 5BG ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2072-9216","authenticated-orcid":false,"given":"Dan","family":"Siskind","sequence":"additional","affiliation":[{"name":"Addiction and Mental Health Service, Metro South Health , Brisbane, QLD 4114 ,","place":["Australia"]},{"name":"Faculty of Medicine, University of Queensland , Brisbane, QLD 4006 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Strawbridge","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 YN77 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeun","family":"Tae","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 YN77 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Keating","sequence":"additional","affiliation":[{"name":"Pharmacy Department, St John of God University Hospital , Dublin A94 FH92 ,","place":["Ireland"]},{"name":"Research and Innovation Hub, St John of God University Hospital , Dublin A94 FH92 ,","place":["Ireland"]},{"name":"School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences , Dublin D02 YN77 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6240-6952","authenticated-orcid":false,"given":"Brian","family":"O\u2019Donoghue","sequence":"additional","affiliation":[{"name":"UCD Centre for Psychosis Research, School of Medicine, University College Dublin , Dublin D04 V1W8 ,","place":["Ireland"]},{"name":"Department of Psychiatry, St Vincent's University Hospital , Dublin D04 T6F4 ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"2026081405130378900_ref1","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2026081405130378900_ref2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1210\/jc.2006-0513","article-title":"Metabolic syndrome: a multiplex cardiovascular risk factor","volume":"92","author":"Grundy","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026081405130378900_ref3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-024-07993-x","article-title":"Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis","volume":"634","author":"Takaoka","year":"2024","journal-title":"Nature."},{"key":"2026081405130378900_ref4","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time course of LDL cholesterol exposure and cardiovascular disease event risk","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026081405130378900_ref5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/ehjqcco\/qcaf105","article-title":"Association between delayed statin initiation after high LDL-cholesterol detection and cardiovascular risk in general health screening examinees","volume":"11","author":"Lee","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026081405130378900_ref6","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/j.cjca.2022.05.002","article-title":"The detection, evaluation, and management of dyslipidemia in children and adolescents","volume":"38","author":"Khoury","year":"2022","journal-title":"Can J Cardiol"},{"key":"2026081405130378900_ref7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet."},{"key":"2026081405130378900_ref8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026081405130378900_ref9","doi-asserted-by":"publisher","first-page":"120479","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis."},{"key":"2026081405130378900_ref10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2026081405130378900_ref11","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/eurheartj\/ehae054","article-title":"Severe mental illness: cardiovascular risk assessment and management","volume":"45","author":"Polcwiartek","year":"2024","journal-title":"Eur Heart J"},{"key":"2026081405130378900_ref12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S2213-8587(23)00086-4","article-title":"Metabolic health and cardiometabolic risk clusters","volume":"11","author":"Stefan","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026081405130378900_ref13","doi-asserted-by":"publisher","first-page":"e024476","DOI":"10.1136\/bmjopen-2018-024476","article-title":"Multimorbidity of cardiometabolic diseases in Chinese adults","volume":"9","author":"Zhang","year":"2019","journal-title":"BMJ Open"},{"key":"2026081405130378900_ref14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"2026081405130378900_ref15","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/S2352-4642(24)00098-1","article-title":"Comparative physiological effects of antipsychotic drugs in children and young people","volume":"8","author":"Rogdaki","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"2026081405130378900_ref16","doi-asserted-by":"publisher","first-page":"e651","DOI":"10.1038\/tp.2015.161","article-title":"A potential mechanism underlying atypical antipsychotics-induced lipid disturbances","volume":"5","author":"Shao","year":"2015","journal-title":"Transl Psychiatry"},{"key":"2026081405130378900_ref17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.schres.2006.06.026","article-title":"Low rates of treatment for hypertension, dyslipidemia, and diabetes in schizophrenia","volume":"86","author":"Nasrallah","year":"2006","journal-title":"Schizophr Res"},{"key":"2026081405130378900_ref18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S2215-0366(25)00031-8","article-title":"INTEGRATE: international guidelines for algorithmic treatment of schizophrenia","volume":"12","author":"McCutcheon","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026081405130378900_ref19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/00048674251406058","article-title":"Australian and New Zealand journal of psychiatry grading of recommendations, assessment, development and evaluations (GRADE) guidelines for the management of schizophrenia","volume":"60","author":"Suetani","year":"2026","journal-title":"Aust N Z J Psychiatry Published online January"},{"key":"2026081405130378900_ref20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2215-0366(25)00170-1","article-title":"Implementing lifestyle interventions in mental health care: third report of the lancet psychiatry physical health commission","volume":"12","author":"Teasdale","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"2026081405130378900_ref21","volume-title":"NICE guideline CG181"},{"key":"2026081405130378900_ref22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Cardiovascular disease in patients with severe mental illness","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"2026081405130378900_ref23","doi-asserted-by":"publisher","first-page":"109618","DOI":"10.1016\/j.abb.2023.109618","article-title":"Understanding the molecular mechanisms of statin pleiotropic effects","volume":"742","author":"Vona","year":"2023","journal-title":"Arch Biochem Biophys"},{"key":"2026081405130378900_ref24","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1001\/jama.2022.13044","article-title":"Statin use for primary prevention of cardiovascular disease","volume":"328","author":"Preventive Services Task Force","year":"2022","journal-title":"JAMA."},{"key":"2026081405130378900_ref25","doi-asserted-by":"publisher","author":"","journal-title":"Br J Psychiatry","DOI":"10.1192\/bjp.2025.10476"},{"key":"2026081405130378900_ref26","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for hypertriglyceridemia","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation."},{"key":"2026081405130378900_ref27","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.bbalip.2011.10.011","article-title":"Fish oil \u2014 how does it reduce plasma triglycerides?","volume":"1821","author":"Shearer","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"2026081405130378900_ref28","doi-asserted-by":"publisher","first-page":"sbag023","DOI":"10.1093\/schbul\/sbag023","article-title":"Clinical practice guideline on the choice of first antipsychotic medicine for females experiencing a first-episode of psychosis","volume":"52","author":"Hynes-Ryan","year":"2026","journal-title":"Schizophr Bull"},{"key":"2026081405130378900_ref29","first-page":"119","article-title":"Antipsychotic prescribing in children and adolescents in England","volume":"10","author":"Radojcic","year":"2023","journal-title":"Lancet Psychiatry"},{"key":"2026081405130378900_ref30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s11096-024-01817-8","article-title":"Psychotropic medication use in children and adolescents in Ireland","volume":"47","author":"Parkin","year":"2025","journal-title":"Int J Clin Pharm"},{"key":"2026081405130378900_ref31","doi-asserted-by":"publisher","first-page":"e12208","DOI":"10.1002\/jcv2.12208","article-title":"Antipsychotic prescribing in Australian general practice","volume":"4","author":"Klau","year":"2024","journal-title":"JCPP Adv"},{"key":"2026081405130378900_ref32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/healthcare12030338","article-title":"Prevalence and cost of antipsychotic prescribing in Ireland","volume":"12","author":"Vaughan","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"2026081405130378900_ref33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","article-title":"GRADE evidence to decision frameworks","volume":"81","author":"Sch\u00fcnemann","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"2026081405130378900_ref34","doi-asserted-by":"publisher","first-page":"e031767","DOI":"10.1136\/bmjopen-2019-031767","article-title":"RIGHT-ad@pt checklist protocol","volume":"9","author":"Song","year":"2019","journal-title":"BMJ Open"},{"key":"2026081405130378900_ref35","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.euf.2021.09.018","article-title":"Patient involvement in guideline development","volume":"7","author":"Bj\u00f6rkqvist","year":"2021","journal-title":"Eur Urol Focus"},{"key":"2026081405130378900_ref36","doi-asserted-by":"publisher","first-page":"642403","DOI":"10.3389\/fpsyt.2021.642403","article-title":"Pharmacological interventions to treat antipsychotic-induced dyslipidemia in schizophrenia patients: a systematic review and meta analysis","volume":"12","author":"Kanagasundaram","year":"2021","journal-title":"Front Psychiatry."},{"key":"2026081405130378900_ref37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2459\/JCM.0000000000001489","article-title":"Effects of statin therapies on individuals taking antipsychotics: a systematic review","volume":"24","author":"Ferrell","year":"2023","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026081405130378900_ref38"},{"key":"2026081405130378900_ref39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.5694\/mja2.52280","article-title":"2023 Australian guideline for cardiovascular disease risk","volume":"220","author":"Nelson","year":"2024","journal-title":"Med J Aust"},{"key":"2026081405130378900_ref40","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society dyslipidemia guidelines","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"2026081405130378900_ref41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1001\/jamacardio.2019.0777","article-title":"2018 AHA\/ACC multisociety guideline on management of blood cholesterol","volume":"4","author":"Grundy","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026081405130378900_ref42","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"AACE\/ACE statement on dyslipidemia management","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"key":"2026081405130378900_ref43","doi-asserted-by":"publisher","first-page":"822","DOI":"10.7326\/M20-4648","article-title":"Dyslipidemia management: VA\/DoD guideline","volume":"173","author":"O\u2019Malley","year":"2020","journal-title":"Ann Intern Med"},{"key":"2026081405130378900_ref44","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on metabolic risk in psychosis","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2026081405130378900_ref45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.12740\/PP\/113222","article-title":"Metabolic risk reduction in schizophrenia","volume":"53","author":"Wichniak","year":"2019","journal-title":"Psychiatr Pol"},{"key":"2026081405130378900_ref46","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3109\/08039488.2010.500397","article-title":"Swedish guidelines on metabolic risk in psychiatric disorders","volume":"64","author":"Gothefors","year":"2010","journal-title":"Nord J Psychiatry"},{"key":"2026081405130378900_ref47","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3399\/bjgp23X735273","article-title":"Lester cardiometabolic resource update","volume":"73","author":"Perry","year":"2023","journal-title":"Br J Gen Pract"},{"key":"2026081405130378900_ref48","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Integrated cardiovascular guidelines for children","volume":"128","author":"Expert Panel; National Heart, Lung, and blood institute","year":"2011","journal-title":"Pediatrics"},{"key":"2026081405130378900_ref49","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1161\/CIR.0000000000000618","article-title":"Cardiovascular risk reduction in high-risk pediatric patients","volume":"139","author":"de Ferranti","year":"2019","journal-title":"Circulation."},{"key":"2026081405130378900_ref50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(25)01578-8","article-title":"Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials","volume":"407","author":"Cholesterol Treatment Trialists' (CTT) Collaboration","year":"2026","journal-title":"Lancet."},{"key":"2026081405130378900_ref51","first-page":"1","article-title":"Cardiovascular disease and osteoporotic fracture risk modelling","volume":"12","author":"Guthrie","year":"2024","journal-title":"Health Soc Care Deliv Res"},{"key":"2026081405130378900_ref52","doi-asserted-by":"publisher","first-page":"118598","DOI":"10.1016\/j.atherosclerosis.2024.118598","article-title":"Statins, ezetimibe in familial hypercholesterolaemia: meta-analysis","volume":"401","author":"Llewellyn","year":"2025","journal-title":"Atherosclerosis."},{"key":"2026081405130378900_ref53","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1192\/j.eurpsy.2024.1766","article-title":"EPA guidance on lifestyle interventions for adults with severe mental illness: a meta-review of the evidence","volume":"67","author":"Maurus","year":"2024","journal-title":"Eur Psychiatry"},{"key":"2026081405130378900_ref54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021366","volume":"24","author":"","journal-title":"Int J Mol Sci"},{"key":"2026081405130378900_ref55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11883-024-01256-w","article-title":"Statin use in children and adolescents","volume":"27","author":"Wilson","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"2026081405130378900_ref56","volume-title":"Lipitor 20 mg Film-Coated Tablets [Summary of Product Characteristics]","year":"2024"},{"key":"2026081405130378900_ref57","volume-title":"Stockley\u2019s Drug Interactions","author":"Preston","year":"2026"},{"key":"2026081405130378900_ref58","volume-title":"Omacor 1000 mg Soft Capsules [Summary of Product Characteristics]","year":"2024"},{"key":"2026081405130378900_ref59","volume-title":"Psychosis and Schizophrenia in Adults: Treatment and Management. NICE Clinical Guideline 178","author":"National Collaborating Centre for Mental Health (UK)","year":"2014"},{"key":"2026081405130378900_ref60","volume-title":"Psychosis and Schizophrenia in Children and Young People: Recognition and Management. NICE Clinical Guideline CG155","author":"National Collaborating Centre for Mental Health (UK)","year":"2013"},{"key":"2026081405130378900_ref61","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2026081405130378900_ref62"},{"key":"2026081405130378900_ref63","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/schbul\/sbae205","article-title":"Metformin for prevention of antipsychotic-induced weight gain","volume":"51","author":"Carolan","year":"2025","journal-title":"Schizophr Bull"},{"key":"2026081405130378900_ref64","doi-asserted-by":"publisher","first-page":"100493","DOI":"10.1016\/j.lanepe.2022.100493","article-title":"PsyMetRiC: metabolic risk calculator validation","volume":"22","author":"Perry","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2026081405130378900_ref65","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"QRISK3 cardiovascular risk algorithm","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ."},{"key":"2026081405130378900_ref66","doi-asserted-by":"publisher","first-page":"j5019","DOI":"10.1136\/bmj.j5019","article-title":"QDiabetes-2018 risk prediction","volume":"359","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ."},{"key":"2026081405130378900_ref67","doi-asserted-by":"publisher","first-page":"e018181","DOI":"10.1136\/bmjopen-2017-018181","article-title":"PRIMROSE cardiovascular risk algorithm","volume":"7","author":"Zomer","year":"2017","journal-title":"BMJ Open"},{"key":"2026081405130378900_ref68","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/wps.20773","article-title":"Lifestyle psychiatry meta-review","volume":"19","author":"Firth","year":"2020","journal-title":"World Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/4\/sbag086\/70461426\/sbag086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/52\/4\/sbag086\/70461426\/sbag086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T09:14:25Z","timestamp":1786698865000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/doi\/10.1093\/schbul\/sbag086\/8749479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbag086","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,7]]},"article-number":"sbag086"}}